- Home
- EXYN vs SCYX Comparison
EXYN vs SCYX Comparison
Compare EXYN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXYN | SCYX |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 44.0M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EXYN | SCYX |
|---|---|---|
| Price | $6.15 | $4.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 104.0K | 80.6K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.76 | $0.57 |
| 52 Week High | $6.98 | $5.62 |
Technical Indicators
Market Signals| Indicator | EXYN | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 69.89 |
| Support Level | $4.76 | $0.67 |
| Resistance Level | N/A | $5.62 |
| Average True Range (ATR) | 0.73 | 0.29 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 62.70 | 88.07 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.